Lexicon Pharmaceuticals Inc LXRX
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LXRX is a good fit for your portfolio.
News
-
Lexicon Pharmaceuticals to Host 2024 Investor Day
-
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
-
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
-
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
-
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin
-
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
-
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Trading Information
- Previous Close Price
- $1.60
- Day Range
- $1.52–1.59
- 52-Week Range
- $0.92–3.79
- Bid/Ask
- $1.54 / $1.60
- Market Cap
- $379.20 Mil
- Volume/Avg
- 1.7 Mil / 4.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 282.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 285
- Website
- https://www.lexpharma.com
Comparables
Valuation
Metric
|
LXRX
|
TVTX
|
RETA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 37.91 |
Price/Book Value | 4.05 | 2.02 | 74.73 |
Price/Sales | 282.83 | 2.76 | 283.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
LXRX
TVTX
RETA
Financial Strength
Metric
|
LXRX
|
TVTX
|
RETA
|
---|---|---|---|
Quick Ratio | 5.42 | 3.31 | 2.82 |
Current Ratio | 5.60 | 3.47 | 3.21 |
Interest Coverage | −13.11 | −34.10 | −1.31 |
Quick Ratio
LXRX
TVTX
RETA
Profitability
Metric
|
LXRX
|
TVTX
|
RETA
|
---|---|---|---|
Return on Assets (Normalized) | −68.99% | −2.68% | −51.74% |
Return on Equity (Normalized) | −130.40% | −12.41% | — |
Return on Invested Capital (Normalized) | −74.77% | −5.04% | −186.99% |
Return on Assets
LXRX
TVTX
RETA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jwqbzmqbj | Cvps | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Smgzghbd | Qddqgnq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cvlmsmtz | Tltbz | $97.8 Bil | |
MRNA
| Moderna Inc | Mprqbrqp | Mhnb | $38.8 Bil | |
ARGX
| argenx SE ADR | Rfkxtrdt | Hytks | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Mskgdlwpq | Rdzn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nwfwptvj | Hknqpg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wssstby | Stmysz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lhtgkspk | Kwcdbsq | $12.5 Bil | |
INCY
| Incyte Corp | Lxxtggpdr | Smtnvlz | $11.5 Bil |